Building Respiratory Support in East Africa Through High Flow Versus Standard Flow Oxygen Evaluation
- Conditions
- Acute Hypoxemia
- Interventions
- Device: High flow oxygenOther: Standard flow oxygen
- Registration Number
- NCT05754034
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Brief Summary
Acute hypoxemia is common and deadly in resource variable settings. While studies in high income countries (HICs) have indicated a possible benefit to high flow oxygen as compared with standard flow oxygen, rigorous studies in low or lower middle income countries (LMICs) have not been performed. Studies in sepsis have demonstrated that interventions that improve outcomes in one context may actually be neutral or harmful in a different context.
The goal of this study is to test whether high flow oxygen results in better outcomes for hypoxemic adult patients, as compared with standard flow oxygen, in five LMIC hospitals. The main questions it aims to answer are:
1. For hypoxemic adults in these LMIC study settings, does high flow oxygen or standard flow oxygen result in lower mortality?
2. What are the facilitators and barriers to using high flow oxygen in these settings?
3. Does high flow or standard flow oxygen use more oxygen?
Participants will be randomized to receive either high flow oxygen through a large nasal cannula, or to receive standard flow oxygen, through nasal cannulas, face masks, or non-rebreather masks. Researchers will compare the outcomes for the two groups, to see if one group of patients has better outcomes than the other.
The study will also examine how much oxygen is used by the two patient groups, as well as other factors relevant to the feasibility of implementation of high flow oxygen in these sites.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1054
- age>=18 years AND
- admitted to a study site hospital within the 24 hours prior to screening AND
- SpO2<90% at time of first assessment OR
- receiving oxygen at time of first assessment
- imminent death (high clinical suspicion of death within 24 hours of admission)
- patient or caregiver refusal of study participation
- history of chronic respiratory failure (SpO2<90% or oxygen dependence for at least three months)
- anatomical factors precluding the use of nasal cannula
- intubation or non-invasive ventilation by the clinical team prior to screening for the trial
- known hypoxemia at transferring facility for >48 hours
- lack of availability of either SFO or HFO devices or supplies at the time of randomization.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description High flow oxygen High flow oxygen Heated and humidified oxygen delivered via high flow oxygen device through nasal cannula, up to 60 liters per minute of flow. Standard flow oxygen Standard flow oxygen Oxygen delivered via standard oxygen devices at standard flows up to 15 liters per minute: nasal cannula, face mask, or nonrebreather mask.
- Primary Outcome Measures
Name Time Method In-hospital mortality Day 90 Death between randomization and end of hospitalization
- Secondary Outcome Measures
Name Time Method 90-day mortality Day 90 Death between randomization and 90 days
Days requiring oxygen Day 90 Days requiring oxygen from randomization to end of hospitalization
Need for mechanical ventilation Day 90 Met objective criteria for need to escalate respiratory therapy to NIV or invasive ventilation, or escalated to NIV or mechanical ventilation
ICU length of stay Day 90 Total days in the ICU during hospitalization
Time to meeting criteria for need for escalation to either NIV or invasive ventilation Day 90 Time to meeting objective clinical criteria for escalation to non-invasive ventilation or invasive ventilation
Time to escalation to either NIV or invasive ventilation Day 90 Time to escalation to non-invasive ventilation or invasive ventilation
90-day functional status Day 90 Functional status 90 days after randomization, as measured by the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
Hospital length of stay Day 90 Days from randomization to hospital discharge or death
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (5)
The University Teaching Hospital of Butare (CHUB)
🇷🇼Huye, Rwanda
AIC Kijabe Hospital
🇰🇪Kijabe, Kenya
Nakuru Level V Hospital
🇰🇪Nakuru, Kenya
Queen Elizabeth Central Hospital
🇲🇼Blantyre, Malawi
The University Teaching Hospital of Kigali (CHUK)
🇷🇼Kigali, Rwanda